Nicotine replacement therapy is an established treatment for smoking cessation, as seen in over 30 years of extensive clinical and post-marketing data.1
No serious treatment related adverse events have been reported in the pivotal clinical trial of NICORETTE® QuickMist mouthspray. Most adverse events reported where mild to moderate in intensity and similar in type to the other oral NRT. In a highly vigilant safety investigation within the Phase 3 clinical study, adverse events were recorded daily during Weeks 1 through 12 by using a pre-specified list of events on an electronic diary and at all clinic visits throughout the study. The most common adverse events were hiccups and throat irritations. Hiccups (57.2%) were significantly more frequent vs. placebo (7.5%) but were mostly of mild intensity and did not affect continued use of the spray or success rates.1,2